Wednesday, February 6, 2013- Who's Going to Buy This Orphan Drugmaker?at Motley Fool (Wed, Feb 6)
- Biogen Idec Paying $3.25 Billion for Full Rights to Tysabriat Motley Fool (Wed, Feb 6)
- Biogen Idec Shares Rise on Deal for Elan's Share of MS Drugat Minyanville (Wed, Feb 6)
- Biogen Stock Hits New High On Tysabri Buyoutat Investor's Business Daily (Wed, Feb 6)
- Biogen gets full rights to 'blockbuster' drugat bizjournals.com (Wed, Feb 6)
- [video] Faber Report: Biogen Idec Buying Stake in MS Drugat CNBC (Wed, Feb 6)
- Early Movers: TWX, CVS, CMI & Moreat CNBC (Wed, Feb 6)
- In Wise Move, Biogen Spends $3.25 Billion For Rest Of Tysabri. Now What Happens To Elan?at Forbes (Wed, Feb 6)
- Elan restructures Tysabri collaboration with Biogenat theflyonthewall.com (Wed, Feb 6)
- Elan Reports Fourth Quarter and Full-Year 2012 Financial ResultsBusiness Wire (Wed, Feb 6)
- Elan Announces Restructuring of Tysabri Collaboration with Biogen IdecBusiness Wire (Wed, Feb 6)
Tuesday, February 5, 2013 Monday, February 4, 2013 Thursday, January 31, 2013 Monday, January 28, 2013 Saturday, January 26, 2013 Wednesday, January 23, 2013 Tuesday, January 22, 2013 Saturday, January 19, 2013 Friday, January 18, 2013Add ELN News to My Yahoo!  | |
|